Il-23-p19 vaccines

13:

• A vaccine kit, comprising:
• the composition of claim 1 and
• a further composition against a disease selected from the group consisting of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, especially type 1 diabetes;
• atherosclerosis, inflammatory bowel disease (IBD)/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies (ANCA-) associated vasculitides, neurodegenerative diseases, atopic dermatitis, graft-versus-host disease, and cancer.

14:

• A peptide, selected from the group consisting of QPEGHHWETQ (SEQ ID No. 98;
• p8461), TQQIPSLSPSQ (SEQ ID No. 99;
• p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100;
• p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101;
• p9440), QPEGHHWETQQIPSLSP (SEQ ID No. 102;
• p9441), QPEGHHWETQQIPSLS (SEQ ID No. 103;
• p8322), QPEGHHWETQQIPS (SEQ ID No. 104;
• p8495), QPEGHHWETQQI P (SEQ ID No. 105;
• p8459-1), QPEGHHWETQQI (SEQ ID No. 106;
• p8460), QPEGHHWETQQ (SEQ ID No. 107;
• p8460-1), QPEGHHWET (SEQ ID No. 108, p8461-1), QPEGHHWE (SEQ ID No. 109;
• p8462), TQQIPSLSPSQPWQ (SEQ ID No. 110, p8397), TQQIPSLSPSQPW (SEQ ID No. 111, p8398), TQQIPSLSPSQP (SEQ ID No. 112, p8399), TQQIPSLSPS (SEQ ID No. 113;
• p8761), TQQIPSLSP (SEQ ID No. 114;
• p8762), and TQQIPSLS (SEQ ID No 115;
• p8763).

15:

• A peptide pair, comprising:
• the peptide of claim 14,
• wherein a first peptide of the peptide pair is selected from the group consisting of QPEGHHWETQQIPS (SEQ ID No. 104;
• p8495), QPEGHHWETQQI P (SEQ ID No. 105;
• p8459-1), QPEGHHWETQQI (SEQ ID No. 106;
• p8460), QPEGHHWETQQ (SEQ ID No. 107;
• p8460-1), QPEGHHWETQ (SEQ ID No. 98;
• p8461), QPEGHHWET (SEQ ID No. 108, p8461-1) and QPEGHHWE (SEQ ID No. 109;
• p8462) and
• a second peptide of the peptide pair is selected from the group consisting of TQQIPSLSPSQPWQ (SEQ ID No. 110, p8397), TQQIPSLSPSQPW (SEQ ID No. 111, p8398), TQQIPSLSPSQP (SEQ ID No. 112, p8399), TQQIPSLSPSQ (SEQ ID No. 99;
• p8400), TQQIPSLSPS (SEQ ID No. 113;
• p8761), TQQIPSLSP (SEQ ID No. 114;
• p8762) and TQQIPSLS (SEQ ID No 115;
• p8763).

16:

• The composition according to claim 1, wherein the peptide is selected from the group consisting of QPEGHHWETQQIPSLS (SEQ ID No. 103;
• p8322), QPEGHHWETQ (SEQ ID No. 98;
• p8461), TQQIPSLSPSQ (SEQ ID No. 99;
• p8400), QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100;
• p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101;
• p9440), and QPEGHHWETQQIPSLSP (SEQ ID No. 102;
• p9441).

17:

• A method of treating an interleukin 23 related disease, comprising:
• administering the composition of claim 1 to a subject in need thereof,
• wherein the interleukin 23 related disease is selected from the group consisting of psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, diabetes, especially type 1 diabetes;
• atherosclerosis, inflammatory bowel disease/M. Crohn, multiple sclerosis, Behcet disease, ankylosing spondylitis, Vogt-Koyanagi-Harada disease, chronic granulomatous disease, hidratenitis suppurtiva, anti-neutrophil cytoplasmic antibodies associated vasculitides, neurodegenerative diseases, atopic dermatitis, graft-versus-host disease, and cancer.

18:

• The composition according to claim 11, wherein the biepitopic vaccine comprises a peptide selected from the group consisting of QPEGHHWETQQIPSLSPSQ (SEQ ID No. 100;
• p9269), QPEGHHWETQQIPSLSPS (SEQ ID No. 101;
• p9440), QPEGHHWETQQIPSLSP (SEQ ID No. 102;
• p9441), and QPEGHHWETQQI PSLS (SEQ ID No. 103;
• p8322).

19:

• The composition according to claim 12,
• wherein a first peptide is selected from the group consisting of QPEGHHWETQQI PS (SEQ ID No. 104;
• p8495), QPEGHHWETQQI P (SEQ ID No. 105;
• p8459-1), QPEGHHWETQQI (SEQ ID No. 106;
• p8460), QPEGHHWETQQ (SEQ ID No. 107;
• p8460-1), QPEGHHWETQ (SEQ ID No. 98;
• p8461), QPEGHHWET (SEQ ID No. 108, p8461-1) and QPEGHHWE (SEQ ID No. 109;
• p8462) and
• a second peptide is selected from the group consisting of TQQIPSLSPSQPWQ (SEQ ID No. 110, p8397), TQQIPSLSPSQPW (SEQ ID No. 111, p8398), TQQIPSLSPSQP (SEQ ID No. 112, p8399), TQQIPSLSPSQ (SEQ ID No. 99;
• p8400), TQQIPSLSPS (SEQ ID No. 113;
• p8761), TQQIPSLSP (SEQ ID No. 114;
• p8762) and TQQIPSLS (SEQ ID No 115;
• p8763).